The notices it replaced
- Reissues: PAR-10-232 Innovative Therapies and Tools for Screenable Disorders in Newborns (R21)
- 2 steps back: PAR-06-059
Replaced by PAR-18-691.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,018,612 in first-year total cost, median $245,494.
Most frequent study sections
- Special Emphasis Panel[ZRG1 GGG-A (50)]2
- Special Emphasis Panel[ZRG1 GGG-B (50)]2
Most frequent institutions
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2
- STATE UNIVERSITY OF NEW YORK AT BUFFALO1
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | T cell-mediated Gene Replacement Therapy1R21HD091461-01A1 | BROWN, BRIAN D | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $251,737 | ZRG1 |
| 2018 | Surfactant Protein-A as a biomarker to predict development of NEC in infants1R21HD094069-01 | ALCORN, JOSEPH L | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $231,000 | ZRG1 |
| 2017 | Novel Treatment Options for Glutaric Aciduria1R21HD088775-01A1 | DEVITA, ROBERT JHOUTEN, SANDER MICHEL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $296,625 | ZRG1 |
| 2016 | Enhancement Newborn Screening to Improve the Efficacy of Cord Blood Transplant for Krabbe Disease1R21HD087818-01 | CARTER, RANDOLPH LEELANGAN, THOMAS J | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $239,250 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.